NASDAQ:MRNA

Moderna Shares Dip With FDA Vote Putting COVID Vaccine Plan to Test

Moderna Shares Dip With FDA Vote Putting COVID Vaccine Plan to Test

Moderna shares fell 2.6% to $46.39 Thursday as an FDA advisory panel met to discuss the 2026-2027 COVID-19 vaccine formula, focusing on the XFG strain. The company reported a Q1 net loss of $1.3 billion and $389 million in revenue, mostly outside the U.S. FDA advisers will review Moderna’s mRNA flu shot for older adults on June 18. Wall Street analysts remain divided on the stock’s outlook.
May 28, 2026

Stock Market Today

  • SpaceX-Linked Stocks Surge as FTSE Rushes IPO Inclusion Amid Destiny Tech100's $1B Share Sale
    May 28, 2026, 10:11 AM EDT. Shares of Destiny Tech100 (DXYZ), VCX, and NASA saw notable rallies following FTSE Russell's fast-tracking of index inclusion rules for large IPOs, ahead of SpaceX's anticipated $1.75 trillion debut. FTSE's rule change allows mega IPOs to enter key indexes after just five trading days, boosting potential passive fund inflows. SpaceX's estimated $70 billion market cap surpasses thresholds for indexes like Russell Top 50 and FTSE All-World. Despite Destiny Tech100's $1 billion at-the-market share offering, retail investors remain bullish, eyeing indirect exposure to SpaceX and private AI ventures. The accelerated inclusion heralds shifts in market dynamics, with SpaceX's debut poised to be the largest IPO ever, fueling significant investor interest.